Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | MMP2 | P08253 | 7/20 | 0.36 |
| ▸ | MMP13 | P45452 | 7/20 | 0.36 |
| ▸ | MMP9 | P14780 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | MMP14 | P50281 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | HBB | P68871 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6434289 | 0.81 | CYP3A4 (0.44) | CYP3A4CYP2C9PKMCYP2C19ABL1 | |
| SCHEMBL6434583 | 0.79 | PRKDC (0.38) | CYP3A4CYP2C9PKMCYP2C19LMNA | |
| SCHEMBL7452465 | 0.79 | ABL1 (0.33) | ABL1RIN1LMNAMAPTMAPK1 | |
| SCHEMBL6433272 | 0.77 | MMP2 (0.44) | CYP3A4CYP2C9PKMCYP2C19ABL1 | |
| SCHEMBL6095578 | 0.74 | CA12 (0.46) | MMP2MMP13MMP9MMP14 | |
| SCHEMBL6435224 | 0.71 | CYP3A4 (0.48) | CYP3A4CYP2C9PKMCYP2C19MMP2 | |
| SCHEMBL6433171 | 0.71 | CYP2C19 (0.45) | CYP3A4CYP2C9PKMCYP2C19LMNA | |
| SCHEMBL5840308 | 0.67 | MEN1 (0.36) | PKMLMNAMMP2MMP13MMP9 | |
| SCHEMBL6584117 | 0.67 | LMNA (0.46) | PKMLMNAKMT2AMEN1TSHR | |
| SCHEMBL31753726 | 0.67 | LMNA (0.46) | PKMLMNAKMT2AMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1181017-B1 | METALLOPROTEASE INHIBITORS | PFIZER LTD (GB) | 2003-04-16 | — | — | EP | claimed |
| US-6511993-B1 | Substituted alpha-aminosulphonyl-acetohydroxamic acids which are inhibitors of zinc-dependent metalloprotease enzymes | PFIZER INC. | 2003-01-28 | — | — | US | claimed |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
| US-20030199440-A1 | Composition for the treatment of damaged tissue | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| EP-1181017-B1 | METALLOPROTEASE INHIBITORS | PFIZER LTD (GB) | 2003-04-16 | — | — | EP | disclosed |
| US-6511993-B1 | Substituted alpha-aminosulphonyl-acetohydroxamic acids which are inhibitors of zinc-dependent metalloprotease enzymes | PFIZER INC. | 2003-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199440-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | CYP3A4 4668/4885CYP2C9 4559/4885PKM 3257/4885 |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | CYP3A4 4668/4885CYP2C9 4559/4885PKM 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.